Skip to main content
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference Press Releases

Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference

SAN DIEGO, April 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 11:20 a.m. EDT (8:20 a.m. PDT) in New York City. A live audio webcast and replay of the presentation will be available in the Investors section…
wpengine
April 3, 2019
Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Press Releases

Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced a total of 10 upcoming presentations summarizing data on the company's lead antifungal rezafungin and its Cloudbreak antiviral program at the 29th…
wpengine
March 26, 2019
Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting Press Releases

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that three rezafungin abstracts have been accepted for presentation at the 45th Annual European Society for Blood and Marrow Transplantation (EBMT) Meeting to be held in Frankfurt, Germany from March 24-27, 2019. Rezafungin is a novel echinocandin antifungal and is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections.…
wpengine
March 7, 2019
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results Press Releases

Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

SAN DIEGO, Feb. 28, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2018 and provided an update on its corporate activities and product pipeline. "Our global Phase 3 ReSTORE trial of rezafungin, for the treatment of patients with candidemia and invasive candidiasis, is enrolling patients and progressing in line with expectations. We also continue…
wpengine
February 28, 2019
Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting Press Releases

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR (formerly the BMT Tandem Meetings) to be held in Houston, Texas from February 20-24, 2019. "The TCT meeting is an important venue for Cidara to share data that demonstrate the potential advantages…
wpengine
February 5, 2019
Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary Press Releases

Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointments of James (Jamie) Levine as chief financial officer and Jessica Oien, J.D., as general counsel and secretary. "We are extremely pleased to welcome Jamie and Jessica to our executive management team. They both have deep, highly relevant experience and distinguished leadership track records in the biotech industry, all of which will be extremely valuable to…
wpengine
December 3, 2018
Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients Press Releases

Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal infections in bone marrow transplantation (BMT) patients at the 60th American Society of Hematology (ASH) Annual Meeting. The 2018 ASH Meeting will be held December 1-4 in San Diego. The rezafungin ASH abstract (2071), titled "Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis…
wpengine
November 27, 2018
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year Press Releases

Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

Employee feedback places Cidara among top 15 small companies in the area SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the second consecutive year. Cidara ranked among the top 15 small companies, and the number one ranked biotech in the small company category, in the San Diego Metro Area. "We are once…
wpengine
November 12, 2018
Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results Press Releases

Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results

SAN DIEGO, Nov. 08, 2018 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2018 and provided an update on its corporate activities and product pipeline. "We made considerable progress during the third quarter of 2018 with the initiation of our Phase 3 ReSTORE trial of rezafungin, for the treatment of invasive candida infections, and the granting by the…
wpengine
November 8, 2018
Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress Press Releases

Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming World Antimicrobial Resistance (AMR) Congress taking place October 25-26, 2018 in Washington, DC. The presentation, titled "Immunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) as countermeasures against multi-drug resistant bacterial infections," is scheduled for 11:10 a.m. Eastern Time on…
wpengine
October 24, 2018